Laura Deming is the founder and full-time partner at The Longevity Fund, an early stage venture capital fund backing companies which target the aging process to treat disease, with investments in gene editing, small molecule therapeutics, and novel methods to treat disease.
From a young age, Ms. Deming has been fascinated by the idea that longevity is a mechanism able to be manipulated.
Up Next in Health and Longevity
-
Steve Horvath + Epigenetic Aging Clocks
Dr. Steve Horvath is a Professor of Human Genetics and Biostatistics at UCLA. His research sits at the intersection of biostatistics, bioinformatics, computational biology, cancer research, genetics, epidemiology, epigenomics, machine learning, and systems biology.
His research team applies thes...
-
Elysium + Maintaining Energy with NAD+
Peter is joined by Elysium Health co-founders Dan Alminana and Eric Marcotulli.
Dan and Eric are on a mission to develop an anti-aging supplement that will add several years to the average human lifespan. For the past decade, they have been researching NAD+, a coenzyme that is required for energ...
-
Darshan Shah + Next Health
How will medical facilities transform as longevity technology demonetizes and democratizes?
In this webinar, Peter tours Los Angeles' Next Health facilities with Founder and CEO (and Abundance 360 member), Darshan Shah, M.D. Their conversation covers topics in longevity, personalized medicine, a...
